A detailed history of Syverson Strege & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Syverson Strege & CO holds 3,250 shares of ABBV stock, worth $595,010. This represents 0.23% of its overall portfolio holdings.

Number of Shares
3,250
Previous 4,056 19.87%
Holding current value
$595,010
Previous $695,000 7.77%
% of portfolio
0.23%
Previous 0.25%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$163.84 - $199.33 $132,055 - $160,659
-806 Reduced 19.87%
3,250 $641,000
Q2 2024

Aug 07, 2024

BUY
$154.79 - $180.76 $627,828 - $733,162
4,056 New
4,056 $695,000
Q2 2022

Aug 11, 2022

BUY
$137.62 - $174.96 $10,321 - $13,122
75 New
75 $11,000
Q1 2022

Apr 13, 2022

SELL
$131.98 - $163.75 $2,639 - $3,275
-20 Closed
0 $0
Q4 2021

Jan 19, 2022

SELL
$107.43 - $135.93 $966 - $1,223
-9 Reduced 31.03%
20 $3,000
Q3 2021

Nov 02, 2021

BUY
$106.4 - $120.78 $3,085 - $3,502
29 New
29 $3,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Syverson Strege & CO Portfolio

Follow Syverson Strege & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Syverson Strege & CO, based on Form 13F filings with the SEC.

News

Stay updated on Syverson Strege & CO with notifications on news.